Diabetogenic Effects of Immunosuppression: An Integrative Analysis.
Post Transplant Diabetes Mellitus (PTDM) affects up to 50% of solid organ transplant recipients and compromises long-term outcomes. The goal of this study was to investigate how immunosuppressants affect gene expression in a manner that increases diabetes risk, by performing integrative analysis on publicly available, high-throughput gene expression data. All high-throughput gene expression datasets of solid organ transplant recipients were retrieved from the Gene Expression Omnibus. Significantly dysregulated genes and pathways were determined, and those in common with type 2 diabetes were identified. THP-1 and HepG2 cells were exposed in vitro to tacrolimus, and validation of genes involved in insulin signaling and glucose metabolism was performed using specific arrays. These cells were then treated with the hypoglycemic agents metformin and insulin to assess for appropriate reversion of specific diabetogenic genes. Insulin signaling and secretion were the most commonly dysregulated pathways that overlapped with diabetes in transplant recipients. KRAS, GRB2, PCK2, BCL2L1, INSL3, DOK3 and PTPN1 were among the most significantly upregulated genes in both immunosuppression and diabetes subsets, and were appropriately reverted by metformin as confirmed in vitro. We discovered that the significantly dysregulated genes in the context of immunosuppression are implicated in insulin signalling and insulin secretion, as a manifestation of pancreatic β-cell function. In vitro validation confirmed key diabetes-related genes in the context of immunosuppression. Further analysis and in vitro validation revealed that metformin optimally reverts diabetogenic genes dysregulated in the context of immunosuppression. The optimal therapeutic management of PTDM needs to be further investigated, taking into account the mechanistic impact of immunosuppressants.